We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Guidance Could Propel Breast Cancer Drugs to Market a Decade Sooner
Guidance Could Propel Breast Cancer Drugs to Market a Decade Sooner
June 6, 2012
Drugmakers could bring breast cancer treatments to market a decade earlier with new FDA guidance on trial designs for evaluating pathologic complete response (pCR) to support accelerated approval of drugs to treat high-risk, early-stage breast cancer.